- Scancell Holdings said the European Patent Office had announced an intention to grant Scancell's patent application for its Moditope immunotherapy platform.

The case was key to the protection of the company's pipeline of vaccines for the treatment of cancer and would provide commercial exclusivity in all major European territories, the company said.

Counterparts to the patent had also been filed in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US.

'By confirming its intention to grant this patent application, the European Patent Office has continued to uphold the validity of Scancell's expanding patent estate,' chief executive Cliff Holloway said.

'This is a key case for the Company as we progress development of our Moditope platform and provides further protection for Scancell's innovative cancer vaccine technologies.'

At 2:28pm: [LON:SCLP] Scancell Holdings PLC share price was +1.15p at 13.4p

Story provided by